Natera (NTRA) commented on recent updates by the NCCN on circulating tumor DNA molecular residual disease testing in the Clinical Practice ...

In its updated guidelines for colon cancer 1 and for rectal cancer 2, NCCN now includes ctDNA as a high risk factor for recurrence in the adjuvant setting, recognizing its prognostic value. This ...

Canaccord Genuity maintained a Buy rating on Natera (NASDAQ:NTRA) shares, with a price target of $180. Trading at $169.27, the $22.35 billion market cap company enjoys strong analyst support, with a ...

The analysis showed that patients with positive blood tests for circulating tumor DNA (ctDNA ... our earlier findings that celecoxib improves survival for PIK3CA mutated colon cancer," says Jeffrey ...

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA who received Celebrex had significantly better rates versus placebo.

A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...

Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test On Tuesday, Guardant Health, Inc. (NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that ...

Medicare now covers Guardant Reveal for monitoring colorectal cancer recurrence ... analysis to detect circulating tumor DNA (ctDNA), a marker of minimal residual disease (MRD).